click below
click below
Normal Size Small Size show me how
Intro of Pharm Tech
Ch. 10 - Basic Biopharmaceutics
Term | Definition |
---|---|
agonists | drug that activate receptors to accelerate or slow normal cellular function |
antagonists | drugs that bind w/ receceptors but do not activate them. They block receptor action by preventing oother drugs or substances from activating them. |
receptor | the cellular material located at the site of action that interacts w/ the drug |
site of action | the location where an administered drug produces an effect |
selective (action) | the characteristic of a drug that makes its action specific to certain receptors and tissues. |
duration of action | the time drug concetration is above the Minimum Effective Concentration (MEC) |
Minimum Effective Concentration (MEC) | the blood concetration needed for a drug to produce a response. |
Minimum Toxic Concentration (MTC) | the upper limit of the therapeutic window. Drug concetrations above the MTC increase the risk of undesired effects. |
onset of action | the time MEC is reached and the response occurs |
therapeutic window | a drug's blood concentration range between its MEC and MTC. |
active transport | the movement of drugs from an area of lower concentration to an area of higher concentration; cellular energy is required. |
disposition | a term sometimes used to refer to all of the ADME processes together. |
elimination | the processes of metabolism and excretion |
hydrophilic | capable of associating w/ or absorbing water. |
hydrophobic | water repelling; cannot associate w/ water. |
lipoidal | fat-like substance |
passive diffusion | the movement of drugs from an area of higher concentrationto lower concentration |
absorption | the movement of a drug from the dosage formulation to the blood |
gastric emptying time | the time a drug will stay in the stomach before it is emptied into the small intestine |
complexation | when different molecules associate or attach to each other |
protein binding | the attachment of a drug molecule to a plasma or tisssue protein, effectively making the drug inactive, but also keeping it within the body. |
enterohepatic cycling | the transfer of drugs and their metabolites from the liver to the bile in the gallbladder, then into the intestine, and then back into circulation |
enzyme | a complex protein that catalyzes chemical reactions |
enzyme induction | the increase in hepatice enzyme activity that results in greater metabolism of drugs |
enzyme inhibition | the decrease in hepatic enzyme activity that results in reduced metabolism of drugs |
first-pass metabolism | the substantial degradation of an orally administered drug caused by enzyme metabolism in the liver before the drug reaches the systemic circulation. |
metabolite | the substance resulting from the body's transformation of an administered drug. |
glomerular filtration | the blood filtering process of the nephron |
nephron | the functional unit of the kidney |
absolute bioavailbility | the bioavailability of a drug product compared to the same drug in a rapidly administered IV solution |
bioavailability | the amount of an administered dose that reaches the general circulation and the rate at which this occurs. |
relative bioavailability | the bioavailability of a drug product compared to the same drug in any other dosage form than a rapidly administered IV solution. |
bioequivalency | the comparison of bioavalability beween two dosage forms. |
pharmaceutical alternative | drug products that contain the same active ingredient, but not necessarily in the same salt form, amount, or dosage form. |
phamaceutical equivalent | drug products that contain identical amounts of the same active ingredient in the same dosage form. |
therapeutic equivalent | pharmaceutical equivalents that produce the same effects in patients |